Latest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
Putting SYNTAX In Context
Posted Sep 02, 2008
at 12:48 PM, EDT
At ESC in Munich, Hot line results from SYNTAX and CARDIA were presented.....what does this mean for deciding about PCI vs CABG?
Previous postsBillets précédents
Ezetimibe in ARBITER 6-HALTS: What lessons can we learn?
No commentsAucun commentaire |
Posted Nov 16, 2009
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
Dabigatran: Crossing a remarkable threshold
No commentsAucun commentaire |
Posted Oct 14, 2009
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
Antiplatelet therapy: A step forward with individualized medicine
5 comments5 commentaires |
Posted Sep 22, 2009
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
Cash for clunkers, cash for lowering obesity rates
4 comments4 commentaires |
Posted Aug 24, 2009
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
Preventing rehospitalization for heart failure
3 comments3 commentaires |
Posted Jul 28, 2009
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
Also from theheart.org
Blogs I read
Who's talking
|
Eric J Topol MD
Director, Scripps Translational Science Institute The Gary and Mary West Chair of Innovative Medicine Chief Academic Officer, Scripps Health La Jolla, CA |














CommentsCommentaires
appreciate this column
The results of SYNTAX trial are interesting but not suprising...and are related to previous trials comparing CABG with PTCA.
I think that we don't take into account the psycological impact of an open heart surgery and we must try to evaluate other situations to select the proper revascularization method such as the need to be ready quickly back to work, age, gender, diabetes and the future need of medication, although most patients need Aspirin, beta blockers, Statins and maybe other antihypertensive drugs.
An important issue is if the patient is going to be sent to surgery during the next year because of the withdrawl of Clopidogrel (in the PTCA group).
The patient must be part of the final decision.
I am personally impressed with the PCI outcomes, particularly in light of the total length and number of stents and the frequent LM stenting. I wonder whether the inability to establish noninferiority of PCI is equivalent to establishing the superiority of CABG for the composite endpoint. Probably not, due to power considerations. The whole composite endpoint approach including repeat TVR likely biased against noninferiority.
I also have difficulty with the meta-analysis in JACC. The COURAGE trial is the largest and provided the best medical therapy. I think it stands on its own. A recent JACC "state of the art" piece appeared somewhat biased in my opinion toward intervention.
In INDAI we have lots of constrains for using multiple DES in a single patient , as CABG surgery is very cost effective , non the less repeat procedures?
Probably there could be a vaible option of making ACS patients stabilize by using one DES at culprit vessel and making the subject stabilize to follow up as any one of COURAGE trial patient with optimal medical and life style approach. Thus taking the advantage of both the great trials in real world senario with the least discomfort to the patients.